Pyrimethamine increases β-hexosaminidase A activity in patients with Late Onset Tay Sachs

Molecular Genetics and Metabolism

Volumn 102, Issue 3, 2011, Pages 356-363

  Osher, Etty ^a   Fattal Valevski, Aviva ^a   Sagie, Liora ^a   Urshanski, Nataly ^a   Amir Levi, Yifat ^a   Katzburg, Sara ^a   Peleg, Leah ^b   Lerman Sagie, Tally ^b   Zimran, Ari ^c   Elstein, Deborah ^c   Navon, Ruth ^b   Stern, Naftali ^a   Valevski, Avi ^b  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

hexosaminidase A; Late Onset Tay Sachs; Pyrimethamine

Indexed keywords

BETA N ACETYLHEXOSAMINIDASE A; PYRIMETHAMINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DOSE RESPONSE; DRUG DOSE INCREASE; ENZYME ACTIVITY; FEMALE; FOLLOW UP; GENE MUTATION; HUMAN; IN VIVO STUDY; LYMPHOCYTE; MALE; MOOD; MOTOR ACTIVITY; PRIORITY JOURNAL; SPEECH; TAY SACHS DISEASE; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; FEMALE; FOLIC ACID ANTAGONISTS; HEXOSAMINIDASE A; HUMANS; LYMPHOCYTES; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PYRIMETHAMINE; TAY-SACHS DISEASE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79851515186     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2010.11.163     Document Type: Article

References (21)

1. Gravel R., Kaback M., Proia R., Sandhoff K., Suzuki K., Suzuki K. The GM2. The Metabolic and Molecular Basis of Inherited Disease 2001, 3827-3876. McGraw-Hill, New York. 8th Ed. C.R. Scriver, A.L. Beaudet, D. Valle, W.S. Sly (Eds.).
2. Leinekugel P., Michel S., Conzelmann E., Sandhoff K. Quantitative correlation between the residual activity of beta-hexosaminidase A and arylsulfatase A and the severity of the resulting lysosomal storage disease. Hum. Genet. 1992, 88:513-523.
3. Neudorfer O., Pastores G.M., Zeng B.J., Gianutsos J., Zaroff C.M., Kolodny E.H. Late-onset Tay-Sachs disease: phenotypic characterization and genotypic correlations in 21 affected patients. Genet. Med. 2005, 7:119-123.
4. Desnick R.J., Schuchman E.H. Enzyme replacement and enhancement therapies: lessons from lysosomal disorders. Nat. Rev. Genet. 2002, 3:954-966.
5. Jeyakumar M., Butters T.D., Cortina-Borja M., Hunnam V., Proia R.L., Perry V.H., Dwek R.A., Platt F.M. Delayed symptom onset and increased life expectancy in Sandhoff disease mice treated with Nbutyldeoxynojirimycin. Proc. Natl Acad. Sci. USA 1999, 96:6388-6393.
6. Shapiro B.E., Pastores G.M., Gianutsos J., Luzy C., Kolodny E.H. Miglustat in late-onset Tay-Sachs disease: a 12-month, randomized, controlled clinical study with 24months of extended treatment. Genet. Med. 2009, 11:425-433.
7. Tropak M.B., Mahuran D. Lending a helping hand, screening chemical libraries for compounds that enhance beta-hexosaminidase A activity in GM2 gangliosidosis cells. FEBS J. 2007, 274:4951-4961.
8. Leport C., Chene G., Morlat P., Luft B.J., Rousseau F., Pueyo S., Hafner R., Miro J., Aubertin J., Salamon R., Vildé J.L. Pyrimethamine for primary prophylaxis of toxoplasmic encephalitis in patients with human immunodeficiency virus infection: a double-blind, randomized trial. ANRS 005-ACTG 154 Group Members. Agence Nationale de Recherche sur leSIDA. AIDS Clinical Trial Group. J. Infect. Dis. 1996, 173:91-97.
9. Weiss L.M., Luft B.J., Tanowitz H.B., Wittner M. Pyrimethamine concentrations in serum during treatment of acute murine experimental toxoplasmosis. Am. J. Trop. Med. Hyg. 1992, 46:288-291.
10. Buxton I.L.O. Pharmacokinetics and pharmacodynamics:the dymamics of drug absorption, distribution, action and elimination. Goodman and Gilman's the Pharmacological Basis of Therapeutics Brunton LL, editor 2006, McGraw-Hill Books, New York.
11. Weiss L.M., Harris C., Berger M., Tanowitz H.B., Wittner M. Pyrimethamine concentrations in serum and cerebrospinal fluid during treatment of acute Toxoplasma encephalitis in patients with AIDS. J. Infect. Dis. 1988, 157:580-583.
12. Maegawa G.H., Tropak M., Buttner J., Stockley T., Kok F., Clarke J.T., Mahuran D.J. Pyrimethamine as a potential pharmacological chaperone for late-onset forms of GM2 gangliosidosis. J. Biol. Chem. 2007, 282:9150-9161.
13. Hauser S.L., Dawson D.M., Lehrich J.R., Beal M.F., Kevy S.V., Propper R.D., Mills J.A., Weiner Intensive H.L. immunosuppressant in progressive multiple sclerosis. A randomized, three arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH. N. Engl. J. Med. 1983, 308:173-180.
14. Brooks B.R., Sanjak M., Ringel S. ALS CNTF Treatment Study (ACTS) Phase I-II Study Group. The Amyotrophic Lateral Sclerosis Functional Rating Scale. Assessment of activities of daily living in patients with Amyotrophic Lateral Sclerosis. Arch. Neurol. 1996, 53:141-147.
15. Tinetti M.E. Performance-oriented assessment of mobility problems in elderly patients. J. Am. Geriatr. Soc. 1986, 34:119-126.
16. Tinetti M., Richman D., Powell L. Falls efficacy as a measure of fear of falling. J. Gerontol 1990, 45:239-243.
17. Kresse H., Fuchs W., Glössl J., Holtfrerich D., Gilberg W. Liberation of N-acetylglucosamine-6-sulfate by human beta-N-acetylhexosaminidase A. J. Biol. Chem. 1981, 256:12926-12932.
18. Bøyum A. Isolation of mononuclear cells and granulocytes from human blood. Scand. J. Clin. Lab. Invest. 1968, 21:77-89.
19. Cao Z., Petroulakis E., Salo T., Triggs-Raine B. Benign HEXA mutations, C739T(R247W) and C745T(R249W), cause beta-hexosaminidase A pseudodeficiency by reducing the alpha-subunit protein levels. J. Biol. Chem. 1997, 272:14975-14982.
20. Clarke J.T., Mahuran D.J., Sathe S., Kolodny E.H., Rigat B.A., Raiman J.A., Tropak M.B. An open-label Phase I/II clinical trial of pyrimethamine for the treatment of patients affected with chronic GM2 gangliosidosis (Tay-Sachs or Sandhoff variants). Mol. Genet. Metab. 2010, Epub ahead of print.
21. Sprecher H., Barr H.M., Slotky J.I., Tzukerman M., Eytan G.D., Assaraf Y.G. Alteration of mitochondrial gene expression and disruption of respiratory function by the lipophilic antifolate pyrimethamine in mammalian cells. J. Biol. Chem. 2007, 282:9150-9161.